Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors

Are you keeping a close watch on PharmaCyte Biotech Inc. (PMCB) and wondering about its financial stability? With shares hitting a 52-week low at $1.03 in April 2025 and a 39.66% value decrease over the past year, it's natural to question the biotech firm's financial health. Despite these challenges, PharmaCyte maintains a strong current ratio of 14.2, signaling robust liquidity, and trades at an attractive Price-to-Book ratio of 0.26. But how does this square with an FDA clinical hold on their pancreatic cancer treatment and a significant decrease in cash reserves from $50.2 million in April 2024 to approximately $16.4 million by January 31, 2025? Dive in to explore a detailed breakdown of PharmaCyte's financial status, recent accounting changes, and what key financial metrics reveal about its investment potential.

PharmaCyte Biotech, Inc. (PMCB) Revenue Analysis

As a development stage company, PharmaCyte Biotech, Inc. (PMCB) currently generates minimal revenue. The company focuses primarily on research and development, with its lead product candidate being Cell-in-a-Box^® for pancreatic cancer and other solid cancerous tumors. Therefore, revenue streams are limited to:

• Licensing agreements: Any income derived from licensing its technology.
• Grant income: Funds received from grants to support research activities.
• Other income: Miscellaneous sources such as interest income.

Given its status, a traditional year-over-year revenue growth analysis may not be applicable. Instead, investors should monitor:

• Progress in clinical trials: Positive results can lead to potential partnerships and future revenue.
• New patents and intellectual property: Expanding the company's portfolio increases its value.
• Strategic collaborations: Partnerships with other companies can provide funding and expertise.

For detailed insights into the company's strategic direction, refer to: Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).

Understanding PharmaCyte Biotech's financial performance requires a focus on factors beyond traditional revenue metrics. Investors should closely monitor the company's cash burn rate, funding runway, and progress in clinical development.

PharmaCyte Biotech, Inc. (PMCB) Profitability Metrics

Analyzing PharmaCyte Biotech, Inc. (PMCB)'s profitability involves examining several key metrics, including gross profit, operating profit, and net profit margins. These metrics provide insights into the company's efficiency in generating profit from its revenue and managing its expenses. Understanding these trends is crucial for investors to assess the company's financial health and long-term viability. For additional details, you can read more at Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors.

As of now, comprehensive profitability data for PharmaCyte Biotech, Inc. (PMCB) for the fiscal year 2024 is not readily available. Typically, the information includes:

• Gross Profit: The revenue remaining after deducting the cost of goods sold (COGS). It indicates how efficiently a company manages its production costs.
• Operating Profit: Calculated by subtracting operating expenses (such as administrative and sales costs) from the gross profit. It reflects the profitability of the core business operations.
• Net Profit: The profit remaining after all expenses, including taxes and interest, are deducted from revenue. It represents the actual profit available to the company's owners.
• Profit Margins: These are ratios that express profit as a percentage of revenue, providing a standardized way to compare profitability over time and across different companies. Key margins include gross profit margin, operating profit margin, and net profit margin.

To provide a clearer picture, here's how profitability metrics are generally structured in financial analysis:

Without specific 2024 data, it's challenging to offer precise insights into PharmaCyte Biotech's current profitability. Investors should consult the company's financial statements and related filings for the most up-to-date information.

PharmaCyte Biotech, Inc. (PMCB) Debt vs. Equity Structure

Understanding how a company finances its operations is crucial for investors. This analysis delves into PharmaCyte Biotech, Inc.'s (PMCB) approach to balancing debt and equity.

Overview of Debt Levels

As of recent financial updates, PharmaCyte Biotech, Inc. (PMCB) reports:

• No Debt: The company is currently reported as debt-free.
• Total Liabilities: The company's total liabilities stand at $3.58 million.

Debt-to-Equity Ratio

PharmaCyte Biotech's debt-to-equity ratio is 0%, indicating that it relies solely on equity to finance its assets. This is notably different from many companies in the biotechnology industry, where leveraging debt is a common practice.

Balancing Debt and Equity

PharmaCyte Biotech has chosen to avoid debt, financing its operations through equity. As of January 31, 2025, the company had approximately $16.4 million in cash and cash equivalents, a decrease from $50.2 million on April 30, 2024. This decrease was due to several factors, including:

• Redemption of preferred stock
• Repurchase of common stock
• Investment activities
• Operating expenses

Equity Financing

PharmaCyte Biotech has actively utilized equity financing. For example, on May 12, 2023, the company announced an equity buyback for 7,750,000 shares, worth $25.19 million. Additionally, on February 3, 2023, there was another buyback announcement for $10 million worth of shares.

Financial Health and Management

Despite not using debt, PharmaCyte Biotech faces financial and operational challenges. A recent report highlighted material weaknesses in internal controls related to segregation of duties and management review controls. The company is actively working to address these issues.

Here is a summary of PharmaCyte Biotech, Inc.'s (PMCB) key balance sheet figures:

For more detailed insights, read the full analysis on Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors.

PharmaCyte Biotech, Inc. (PMCB) Liquidity and Solvency

When evaluating PharmaCyte Biotech, Inc.'s financial health, understanding its liquidity and solvency is crucial for investors. Liquidity refers to the company's ability to meet its short-term obligations, while solvency indicates its ability to meet long-term obligations.

Here's an overview of key liquidity measures:

• Current Ratio: This ratio measures a company's ability to pay off its current liabilities with its current assets. A current ratio of 1 or higher generally indicates good liquidity.
• Quick Ratio: Also known as the acid-test ratio, this is similar to the current ratio but excludes inventory, which is often less liquid. A quick ratio of 1 or higher is also generally preferred.
• Working Capital: This is the difference between a company's current assets and current liabilities. Positive working capital indicates that a company has enough short-term assets to cover its short-term liabilities.

Analyzing PharmaCyte Biotech, Inc.'s cash flow statements provides insights into its liquidity. The cash flow statement is divided into three sections:

• Operating Activities: This section shows the cash generated or used from the company's core business operations.
• Investing Activities: This section includes cash flows from the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E).
• Financing Activities: This section includes cash flows from debt, equity, and dividends.

Monitoring the trends in these cash flow categories can reveal whether the company is generating enough cash from its operations to fund its investments and meet its debt obligations.

For more detailed information, you can check out: Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors

PharmaCyte Biotech, Inc. (PMCB) Valuation Analysis

Determining whether PharmaCyte Biotech, Inc. (PMCB) is overvalued or undervalued requires a multifaceted approach, considering various financial metrics and market indicators. Here's an overview of key valuation aspects:

Price-to-Earnings (P/E) Ratio: As PharmaCyte Biotech, Inc. is currently not profitable, the P/E ratio is not applicable. This is because the P/E ratio, which compares a company's stock price to its earnings per share, is typically used for companies with positive earnings.

Price-to-Book (P/B) Ratio: The P/B ratio compares a company's market capitalization to its book value of equity. It helps investors understand how much they are paying for the net assets of the company. As of December 31, 2023, PharmaCyte Biotech, Inc.'s book value was reported as $4.884 million. However, a current P/B ratio relative to its stock price isn't available without real-time stock data and should be calculated based on the latest available information.

Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Similar to the P/E ratio, the EV/EBITDA ratio is less relevant for PharmaCyte Biotech, Inc. at this time due to its lack of positive earnings. The EV/EBITDA ratio is used to assess a company's overall value relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). For companies without positive EBITDA, this metric is not useful.

Stock Price Trends: Monitoring the stock price trends over the last 12 months provides insights into market sentiment and investor confidence. Recent data is essential to gauge current market perception. Based on the latest information available, on April 18, 2025, PharmaCyte Biotech Inc. (PMCB) is trading at $0.0249 per share.

Dividend Yield and Payout Ratios: PharmaCyte Biotech, Inc. does not currently offer dividends. Therefore, dividend yield and payout ratios are not applicable.

Analyst Consensus: Analyst ratings can offer a perspective on the stock's potential. It is important to review the most recent analyst reports to understand their recommendations (buy, hold, or sell) and price targets. As of now, comprehensive analyst consensus specific to PharmaCyte Biotech, Inc.'s valuation is not readily available but should be checked on financial analysis platforms for the most up-to-date assessments.

Additional factors to consider in the valuation include:

• Cash Flow and Runway: Evaluate the company's cash reserves against its burn rate to estimate its operational runway.
• Pipeline Progress: Assess the advancement of its drug candidates through clinical trials.
• Market Conditions: Consider the overall biotech market and any specific factors affecting PharmaCyte Biotech, Inc.'s prospects.

For more insights into the company's direction, see: Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).

PharmaCyte Biotech, Inc. (PMCB) Risk Factors

PharmaCyte Biotech, Inc. (PMCB) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges, external market pressures, and regulatory hurdles inherent to the biotechnology industry.

Here's an overview of the key risks:

• Industry Competition: PharmaCyte operates in a highly competitive environment. Success depends on securing patents, developing proprietary products, and navigating clinical trials effectively.
• Regulatory Changes: The biotechnology industry is heavily regulated. Changes in regulatory requirements can significantly affect the approval process for PharmaCyte's products, leading to delays and increased costs.
• Market Conditions: Unfavorable market conditions, including economic downturns or shifts in investor sentiment, can impact PharmaCyte's ability to raise capital and maintain financial stability.

Specific risks highlighted in recent filings and reports include:

• Operational Risks: These involve challenges in scaling up production, managing supply chains, and ensuring product quality.
• Financial Risks: PharmaCyte may face difficulties in securing sufficient funding to support its research and development activities.
• Strategic Risks: The company's strategic decisions, such as focusing on specific product candidates or markets, may not yield the expected results.

Mitigation strategies and plans, when available, are crucial for addressing these risks. For instance, diversifying funding sources, strengthening intellectual property protection, and implementing robust quality control measures can help mitigate potential negative impacts.

For further insights into PharmaCyte Biotech, Inc.'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).

PharmaCyte Biotech, Inc. (PMCB) Growth Opportunities

For PharmaCyte Biotech, Inc. (PMCB), evaluating future growth prospects requires a comprehensive look at several key factors. These include product innovation, potential market expansion, strategic initiatives, and the competitive landscape.

As of now, pinpointing precise revenue growth projections and earnings estimates for PharmaCyte Biotech, Inc. (PMCB) is challenging due to the company's current financial status and lack of recent financial filings. Investors often depend on detailed financial data to forecast future performance, but without this, it's tough to provide a specific outlook. Keep an eye on official announcements and filings for the most reliable insights.

Key elements that could drive PharmaCyte Biotech, Inc.'s (PMCB) growth include:

• Product Innovations: Advancements in their core technology or the development of new therapies.
• Market Expansions: Successfully entering new geographic markets or targeting different patient populations.
• Strategic Partnerships: Collaborations with other companies for research, development, or distribution.

To provide a clearer view, a SWOT analysis can outline PharmaCyte Biotech, Inc.'s (PMCB) strengths, weaknesses, opportunities, and threats:

Analyzing these components helps stakeholders gauge the potential trajectory of PharmaCyte Biotech, Inc. (PMCB) and its ability to deliver value in the biopharmaceutical sector.

More insights can be found here: Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors